Cadex Genomics | Alibrex

Real-time therapy monitoring for late-stage cancer patie...


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Cadex Genomics® develops and markets liquid-based molecular assays used by physicians to improve care for their cancer patients. Our initial focus is a qPCR-based test, named Alibrex®, which provides real-time insight into therapy response for patients with stage IV solid tumors.


6.5M doses of Stage IV drugs will be administered in North America in 2021, 29.2M doses administered globally at a cost of +$40B. 

Cancer patients and families would avoid months of uncertainty, wasted time, unchecked tumor growth, avoidable toxic side effects and high costs.  

Alibrex is a blood-based diagnostic test that uses widely available and accepted lab methodology with a six-hour turnaround time. It delivers real-time cancer therapy monitoring results that identify ineffective therapy within 2-3 weeks after a patient starts a cycle of therapy, rather than 2-3 months. If therapy isn’t working, patients and care providers know sooner and can consider a different therapy.

Alibrex is objective, precise, reproducible with 100% specificity, is tumor and therapy type agnostic, cost effective, and fits seamlessly into existing patient/physician workflow.

Alibrex has the potential to improve the cancer patient’s quality of life and reduce the cost of care for patients and health insurance companies.

Alibrex scans the cancer patient’s blood rather than relying solely on radiological scans. It requires 2 blood draws: one prior to a cycle of treatment and another 12 to 21 days after a cycle of treatment. The blood draws are obtained during regular scheduled appointments with the patient’s physician. Alibrex analyzes the blood to determine if the patient’s primary tumor is growing, indicating that the patient’s therapy is not working.

Alibrex uses qPCR, patented methods and DNA targets to measure very small changes in cfDNA levels with great precision and accuracy. Cadex Genomics also has patented technology to filter out cfDNA that are unrelated to a patient’s cancer.

Alibrex has a turn-around time of hours rather than days, which is critical for this intended use. The cost to run the Alibrex test is low, enabling pricing that delivers cost savings in different geographies and a positive gross margin to Cadex Genomics.

Bill Haack, President & CEO | Mr. Haack has over 20 years of experience in life sciences. He started his career at Genentech, where he led the Sales Operations team and the successful launch of Rituxan and Herceptin. He was an early employee at Genomic Health, where he helped lead and was instrumental in the success of the launch and commercial success of all three Oncotype DX products. Under Mr. Haack’s leadership, Genomic Health grew from a zero-revenue company to over $300M in annual revenues. Mr. Haack also led the launch of Genomic Health in Europe, where he led the start-up’s headquarters in Geneva and the establishment of commercial teams in the United Kingdom, France, Italy, and Germany. Mr. Haack holds an MA degree in Economics and Econometrics.

Sudhir Sinha, Ph.D., Chief Science Officer | Dr. Sinha is also the CEO of InnoGenomics Technologies, LLC, and an adjunct Professor of Biochemistry and Molecular Biology at the Tulane University School of Medicine in New Orleans. He has over 36 years of experience in biochemical research, Cancer Biomarkers research, and human DNA genotyping and assay commercialization. Before starting InnoGenomics, Dr. Sinha established and served as the Founder, President and Lab Director of ReliaGene Technologies. As President and Chief Scientist at ReliaGene, one of Dr. Sinha’s major achievements was designing and producing the first commercial Y-STR DNA testing kit. He was awarded an export promotion award by the US department of Commerce for the worldwide export of this novel DNA test kit. Dr. Sinha built ReliaGene from a two-employee company into a 90-employee company and successfully sold ReliaGene in 2007 to Orchid-Cellmark, which is now part of Laboratory Corporation of America. Dr. Sinha earned his Ph.D. in Chemistry from the Indian Institute of Technology, Kanpur and completed hisPost-Doctoral Fellowship in Biochemistry and Molecular Biology from the University of Miami, Florida.

Christer Svedman, M.D., Ph.D., Chief Medical Advisor | Dr. Svedman previously worked at GlaxoSmithKline and Genomic Health. While at Genomic Health he built and led the medical affairs department for Europe and was a member of development teams for breast cancer, renal cancer, and liquid biopsy tests as Senior Director of Oncology Development. Dr. Svedman is a medical oncologist with over 20 years of professional experience in clinical oncology, pharma, biotech, and molecular diagnostics. He received his MD and Ph. D from Lund University.

Patrick Hall, D.Ph., SVP, Medical Affairs | Dr. Hall’s career started at Genentech, where he was on the medical affairs team that launched Rituxan and Herceptin. Dr. Hall was also a member of the Rituxan and Herceptin clinical development teams at Genentech, facilitating and monitoring clinical trials. At Genomic Health, Dr. Hall formed and led the medical science liaison team and was involved with the launch of the Breast, Colon and Prostate assays. Dr. Hall was the Executive Director of Medical Affairs at Castle Biosciences and the first Medical employee, where he established a medical affairs team to support the company’s cutaneous melanoma test. He has more than 20 years of industry experience.

Lyssa Friedman, RN, MPA, SVP Medical Operations | Ms. Friedman has built and led successful clinical operations teams at multiple diagnostics companies. While leading clinical operations at Seer, she built the clinical operations group with over 40 sites activated in two studies over six months and developed the medical affairs and first product reimbursement strategies. As VP of Clinical Operations at Veracyte, she oversaw clinical studies leading to product launches, pipeline development and positive coverage decisions across the public and private sectors. She provides clinical development and medical affairs consulting services to diagnostic companies across indications, is a frequent speaker on diagnostic development and clinical and regulatory affairs and has authored more than a dozen peer-reviewed publications.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the platform

Copyright © 2019 All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.